Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01652716 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 377
- Enrollment target
NCT01652716: Completed Phase 3 study, sponsored by AstraZeneca.
NCT01652716 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 377 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01652716, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 377 participants
- Enrollment target
Study Summary
To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with type 2 diabetes mellitus. To examine the long-term (52 weeks of treatment) safety and effect on glucose control of exenatide suspension administered once weekly in subjects with type 2 diabetes mellitus.
Primary Outcome
The primary objective of this study was to compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with type 2 diabetes mellitus.
Interventions
- DRUG Exenatide once weekly suspension
- DRUG Exenatide twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 377 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-08 |
| Phase | Phase 3 |
What the finished NCT01652716 record still lists
NCT01652716 is an interventional study that assigns participants to a tested intervention. The registered 377 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 2 interventions - of which Exenatide once weekly suspension is the first listed.
NCT01652716 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01652716 about?
NCT01652716 is a clinical study titled "Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes". To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with type 2 diabetes mellitus. To examine the long-term (52 weeks of treatment) safety and effect on glucose control of ...
What is the current status of trial NCT01652716?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 377 participants. The study started on 2013-01. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01652716?
The interventions under investigation include: Exenatide once weekly suspension (DRUG), Exenatide twice daily (DRUG).
Who is sponsoring clinical trial NCT01652716?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01652716's enrollment target sits among peer trials
377 988th of 2000 higher than 1,013 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07024784 · 377 participants · Phase 2
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- NCT04254185 · 378 participants · NA
Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow
- NCT06616584 · 378 participants · Phase 2
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia